专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110104118A1 COMPOSITIONS AND METHODS FOR THERAPEUTIC USE 审中-公开
标题翻译：用于治疗用途的组合物和方法
公开(公告)号：US20110104118A1
公开(公告)日：2011-05-05
申请号：US12912496
申请日：2010-10-26
申请人： Heidrun Engler , Bernard G. Huyghe , Daniel C. Maneval , Paul Shabram
发明人： Heidrun Engler , Bernard G. Huyghe , Daniel C. Maneval , Paul Shabram
IPC分类号： A61K48/00 , A61P35/00
CPC分类号： A61K47/186 , A61K9/0019 , A61K38/1709 , A61K47/10 , A61K48/00 , C07K14/4736 , C07K14/4746 , C12N15/87 , C12N2799/022
摘要： A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.
摘要翻译：一种用于使用基因递送系统（例如病毒载体递送系统）治疗癌症的方法和药物组合物，其包含治疗性基因如p53或成视网膜细胞瘤肿瘤抑制基因，其中所述基因递送系统配制在包含递送 - 增强剂如乙醇或洗涤剂。

2. 发明授权

US07002027B1 Compositions and methods for therapeutic use 失效
标题翻译：用于治疗用途的组合物和方法
公开(公告)号：US07002027B1
公开(公告)日：2006-02-21
申请号：US08889355
申请日：1997-07-08
申请人： Heidrun Engler , Tattanahalli L. Nagabhushan , Stephen Kenneth Youngster
发明人： Heidrun Engler , Tattanahalli L. Nagabhushan , Stephen Kenneth Youngster
IPC分类号： C07J9/00 , C07H1/00
CPC分类号： A61K48/00
摘要： The present invention is directed to compositions and methods of treating cancer by gene therapy using a therapeutic gene formulated in a buffer comprising a delivery-enhancing agent. The delivery-enhancing agents of the invention can be used to formulate therapeutic or diagnostic agents, such as proteins, nucleic acids, antisense RNA, small molecules, etc., for administration to any tissue or organ having an epithelial membrane. The delivery-enhancing agents include detergents, alcohols, surfactants and other molecules.
摘要翻译：本发明涉及通过使用配制在包含递送增强剂的缓冲液中的治疗基因进行基因治疗来治疗癌症的组合物和方法。本发明的递送增强剂可用于配制治疗或诊断试剂，例如蛋白质，核酸，反义RNA，小分子等，用于给予具有上皮膜的任何组织或器官。递送增强剂包括洗涤剂，醇，表面活性剂和其它分子。

3. 发明授权

US4600721A Pharmaceutical preparation 失效
标题翻译：药物制剂
公开(公告)号：US4600721A
公开(公告)日：1986-07-15
申请号：US716408
申请日：1985-03-27
申请人： Peter Morsdorf , Helmut Schickaneder , Heidrun Engler , Istvan Szelenyi , Kurt H. Ahrens , Kay Brune
发明人： Peter Morsdorf , Helmut Schickaneder , Heidrun Engler , Istvan Szelenyi , Kurt H. Ahrens , Kay Brune
IPC分类号： A61K31/42 , A61K31/423 , A61K31/425 , A61K31/428 , A61P11/00 , A61P17/00 , A61P27/02 , A61P27/14 , A61P29/00 , A61P37/08 , A61P43/00 , C07D263/58 , C07D277/82
CPC分类号： C07D263/58 , A61K31/42 , A61K31/425 , C07D277/82
摘要： Pharmaceutical preparations having an antiphlogistic action are described. The preparations contain, as active ingredient, a benzazole derivative corresponding to the general tautomeric formulae I ##STR1## wherein X represents a sulphur or oxygen atom and R.sup.1 represents a hydrogen atom and R.sup.2 a hydroxymethyl, formyl, lower carbalkoxy or lower acyl group or R.sup.1 and R.sup.2 together represent the group ##STR2## wherein R.sup.3 and R.sup.4 denote, independently of one another, a hydrogen atom or a C.sub.1 -C.sub.6 -alkyl group, or they contain a physiologically acceptable salt thereof. These pharmaceutical preparations are suitable in particular for the treatment of inflammatory conditions and for inhibiting the lipoxygenase and/or cyclooxygenase route of arachidonic acid metabolism.
摘要翻译：描述具有消炎作用的药物制剂。该制剂含有作为活性成分的对应于一般互变异构体I（I）的苯并唑衍生物，其中X表示硫或氧原子，R1表示氢原子，R2表示羟甲基，甲酰基，低级烷氧羰基或低级酰基基团或R 1和R 2一起表示基团，其中R 3和R 4彼此独立地表示氢原子或C 1 -C 6烷基，或它们含有其生理上可接受的盐。这些药物制剂特别适用于治疗炎性病症和抑制花生四烯酸代谢的脂氧合酶和/或环氧合酶途径。

4. 发明申请

US20100028431A1 COMPOSITIONS AND METHODS FOR THERAPEUTIC USE 有权
标题翻译：用于治疗用途的组合物和方法
公开(公告)号：US20100028431A1
公开(公告)日：2010-02-04
申请号：US12422807
申请日：2009-04-13
申请人： Heidrun Engler , Tattanahalli L. Nagabhushan , Stephen Kenneth Youngster
发明人： Heidrun Engler , Tattanahalli L. Nagabhushan , Stephen Kenneth Youngster
IPC分类号： A61K9/10 , A61K31/70 , A61K31/7016 , A61K38/16 , A61K31/7088 , C08B37/00 , A61P35/00
CPC分类号： A61K48/00
摘要： A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
摘要翻译：一种用于增强治疗剂转移至细胞的方法和药物组合物，其中所述治疗剂配制在包含式I化合物的缓冲液中：其中：n为2-8的整数; X1是胆酸基或脱氧胆酸基; X2和X3各自独立地选自胆酸基，脱氧胆酸基和糖基，其中所述糖基选自戊糖单糖基，己糖单糖基，戊糖 - 戊糖基二糖基团，己糖 - 己糖二糖基团，戊糖 - 己糖二糖基团和己糖 - 六糖二糖基团; 并且其中X 2和X 3中的至少一个是糖基团。

5. 发明申请

US20050025742A1 Methods and compositions for interferon therapy 审中-公开
标题翻译：用于干扰素治疗的方法和组合物
公开(公告)号：US20050025742A1
公开(公告)日：2005-02-03
申请号：US10861654
申请日：2004-06-04
申请人： Heidrun Engler , Tattanahalli Nagabhushan , Stephen Youngster , Robert Connor
发明人： Heidrun Engler , Tattanahalli Nagabhushan , Stephen Youngster , Robert Connor
IPC分类号： A61K20060101 , A61K9/00 , A61K38/21 , A61K48/00
CPC分类号： A61K9/0034 , A61K38/21
摘要： Methods and pharmaceutical compositions for administering protein or gene therapy to tissues or organs having an epithelial cell layer are provided. A protein or nucleic acid encoding the protein is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the delivery of the interferon or nucleic acid to the cells of the target tissues or organs. The methods and combinations are particularly useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an alpha-interferon or a gene delivery system encoding the interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 10 to 1000 fold increased in interferon levels and activity may be observed with the use of a SYN3 formulation as opposed to a PBS formulation of the same interferon protein or interferon gene delivery system.
摘要翻译：提供了用于对具有上皮细胞层的组织或器官进行蛋白质或基因治疗的方法和药物组合物。将编码蛋白质的蛋白质或核酸与目标组织或器官联合施用递送增强剂的组合施用，所述递送增强剂增加干扰素或核酸向靶组织或器官的细胞递送。所述方法和组合在治疗癌症和其它对干扰素治疗有反应的病症方面特别有用。示例性方法包括向膀胱经尿道膀胱内施用治疗有效量的药物组合物，其包含α-干扰素或编码干扰素和SYN3或SYN3同源物或类似物的基因递送系统。在膀胱中，与使用相同干扰素蛋白或干扰素基因递送系统的PBS制剂相比，使用SYN3制剂可以观察到高达10至1000倍的干扰素水平和活性。

6. 发明授权

US4921856A Dihydropyridazinone derivatives, a process for their preparation and pharmaceutical preparations containing these compounds 失效
标题翻译：二氢哒嗪酮衍生物，其制备方法和含有这些化合物的药物制剂
公开(公告)号：US4921856A
公开(公告)日：1990-05-01
申请号：US176689
申请日：1988-04-01
申请人： Helmut Schickaneder , Peter Morsdorf , Volker Pfahlert , Heidrun Engler , Kurt H. Ahrens
发明人： Helmut Schickaneder , Peter Morsdorf , Volker Pfahlert , Heidrun Engler , Kurt H. Ahrens
IPC分类号： A61K31/50 , A61P9/04 , C07D237/04 , C07D403/10 , C07D403/12
CPC分类号： C07D403/10 , C07D237/04 , C07D403/12
摘要： New dihydropryidazinone derivatives corresponding to the following formula ##STR1## and a process for their preparation and pharmaceutical preparations containing these compounds are described. These compounds are effective positively inotropic substances with an improved therapeutic profile.
摘要翻译：描述了对应于下式（I）的新的二氢哒嗪酮衍生物及其制备方法和含有这些化合物的药物制剂。这些化合物是具有改善的治疗特征的有效的正性肌力物质。

7. 发明授权

US08022044B2 Compositions and methods for therapeutic use 有权
标题翻译：用于治疗用途的组合物和方法
公开(公告)号：US08022044B2
公开(公告)日：2011-09-20
申请号：US12422807
申请日：2009-04-13
申请人： Heidrun Engler , Tattanahalli L. Nagabhushan , Stephen Kenneth Youngster
发明人： Heidrun Engler , Tattanahalli L. Nagabhushan , Stephen Kenneth Youngster
IPC分类号： A61K31/70
CPC分类号： A61K48/00
摘要： A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
摘要翻译：一种用于增强治疗剂转移至细胞的方法和药物组合物，其中所述治疗剂配制在包含式I化合物的缓冲液中：其中：n为2-8的整数; X1是胆酸基或脱氧胆酸基; X2和X3各自独立地选自胆酸基，脱氧胆酸基和糖基，其中所述糖基选自戊糖单糖基，己糖单糖基，戊糖 - 戊糖基二糖基团，己糖 - 己糖二糖基团，戊糖 - 己糖二糖基团和己糖 - 六糖二糖基团; 并且其中X 2和X 3中的至少一个是糖基团。

8. 发明授权

US06312681B1 Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems 失效
标题翻译：使用重组病毒载体递送系统治疗癌症的组合物和方法
公开(公告)号：US06312681B1
公开(公告)日：2001-11-06
申请号：US08938089
申请日：1997-09-26
申请人： Heidrun Engler , Dan Maneval
发明人： Heidrun Engler , Dan Maneval
IPC分类号： A61K4800
CPC分类号： A61K47/186 , A61K9/0019 , A61K38/1709 , A61K47/10 , A61K48/00 , C07K14/4736 , C07K14/4746 , C12N15/87 , C12N2799/022
摘要： A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol.
摘要翻译：用于使用基因递送系统（例如病毒载体递送系统）治疗癌症的方法和药物组合物，其包含治疗基因，其中所述基因递送系统配制在包含递送增强剂如乙醇的缓冲液中。

9. 发明授权

US6165779A Compositions and methods for therapeutic use 失效
公开(公告)号：US6165779A
公开(公告)日：2000-12-26
申请号：US779627
申请日：1997-01-07
申请人： Heidrun Engler , Bernard G. Huyghe , Daniel C. Maneval , Paul Shabram
发明人： Heidrun Engler , Bernard G. Huyghe , Daniel C. Maneval , Paul Shabram
IPC分类号： A61K38/17 , A61K47/10 , A61K47/18 , A61K48/00 , C07K14/47 , C12N15/87 , C12N15/63 , A61K38/00 , C12N7/00
CPC分类号： A61K47/186 , A61K9/0019 , A61K38/1709 , A61K47/10 , A61K48/00 , C07K14/4736 , C07K14/4746 , C12N15/87 , C12N2799/022
摘要： A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.

10. 发明授权

US5108998A Cardiotonic thiadiazine derivatives 失效
标题翻译：心脏噻二嗪衍生物
公开(公告)号：US5108998A
公开(公告)日：1992-04-28
申请号：US512812
申请日：1990-04-23
申请人： Peter Morsdorf , Heidrun Engler , Reinhold Weidner , Rolf Herter , Kurt-Henning Ahrens
发明人： Peter Morsdorf , Heidrun Engler , Reinhold Weidner , Rolf Herter , Kurt-Henning Ahrens
IPC分类号： C07D233/64 , A61K31/53 , A61K31/54 , A61P9/04 , C07D285/16 , C07D403/12 , C07D403/14 , C07D417/12 , C07D417/14
CPC分类号： C07D403/12 , C07D403/14 , C07D417/12 , C07D417/14
摘要： New diazine derivatives corresponding to the general formula I ##STR1## and the physiologically acceptable salts thereof are described. The compounds according to the invention are new positive inotropic compounds having a higher and/or more selective action than compounds hitherto known and are therefore suitable for the treatment and prevention of diseases of the heart and circulation.
摘要翻译：描述了对应于通式I（I）的新的二嗪衍生物及其生理上可接受的盐。根据本发明的化合物是具有比迄今已知的化合物更高和/或更多选择性作用的新的正性肌力复合物，因此适用于治疗和预防心脏和血液循环的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式